Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017
Publication Date May 2017
Product Type Report
Pages 165
Single User License help $ 2000.00
Site User License help $ 4000.00
Corporate User License help $ 6000.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 12, 7, 10 and 2 respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Companies Mentioned

AnGes MG Inc AstraZeneca Plc Athera Biotechnologies AB Athersys Inc Bayer AG Betagenon AB BiogenCell Ltd CardioVascular BioTherapeutics Inc Celgene Corp Diffusion Pharmaceuticals Inc Foresee Pharmaceuticals LLC Hemostemix Ltd ID Pharma Co Ltd Juventas Therapeutics Inc LipimetiX Development Inc miRagen Therapeutics Inc Novartis AG Nuo Therapeutics Inc Proteon Therapeutics Inc Recardio GmbH Resverlogix Corp Sigma-Tau SpA Stemedica Cell Technologies Inc Theravasc Inc VESSL Therapeutics Ltd ViroMed Co Ltd Yuyu Pharma Inc

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 7
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Products under Development by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 22
AnGes MG Inc 22
AstraZeneca Plc 22
Athera Biotechnologies AB 23
Athersys Inc 23
Bayer AG 24
Betagenon AB 24
BiogenCell Ltd 25
CardioVascular BioTherapeutics Inc 25
Celgene Corp 26
Diffusion Pharmaceuticals Inc 26
Foresee Pharmaceuticals LLC 27
Hemostemix Ltd 27
ID Pharma Co Ltd 28
Juventas Therapeutics Inc 28
LipimetiX Development Inc 29
miRagen Therapeutics Inc 29
Novartis AG 30
Nuo Therapeutics Inc 30
Proteon Therapeutics Inc 31
Recardio GmbH 31
Resverlogix Corp 32
Sigma-Tau SpA 32
Stemedica Cell Technologies Inc 33
Theravasc Inc 33
VESSL Therapeutics Ltd 34
ViroMed Co Ltd 34
Yuyu Pharma Inc 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles 36
ACP-01 - Drug Profile 36
AEM-28 - Drug Profile 39
ALD-301 - Drug Profile 41
alprostadil - Drug Profile 44
apabetalone - Drug Profile 46
BAY-1193397 - Drug Profile 58
beperminogene perplasmid - Drug Profile 59
BGC-101 - Drug Profile 64
canakinumab - Drug Profile 65
CVBT-141C - Drug Profile 71
DVC-10101 - Drug Profile 72
ELS-140 - Drug Profile 73
FP-045 - Drug Profile 74
JVS-100 - Drug Profile 75
levocarnitine propionate hydrochloride - Drug Profile 80
MRG-110 - Drug Profile 81
MultiGeneAngio - Drug Profile 82
MultiGeneGraft - Drug Profile 83
O-304 - Drug Profile 84
PC-mAb - Drug Profile 86
PDA-002 - Drug Profile 88
PF-05285401 - Drug Profile 89
REC-03 - Drug Profile 101
Rejuveinix - Drug Profile 102
rivaroxaban - Drug Profile 103
sodium nitrite SR - Drug Profile 119
Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders - Drug Profile 121
transcrocetinate sodium - Drug Profile 126
TXA-127 - Drug Profile 130
TXA-302 - Drug Profile 134
V-10 - Drug Profile 135
VM-202 - Drug Profile 136
vonapanitase - Drug Profile 140
YY-984 - Drug Profile 146
zibotentan - Drug Profile 147
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 149
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 151
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 152
Featured News & Press Releases 152
Appendix 162
Methodology 162
Coverage 162
Secondary Research 162
Primary Research 162
Expert Panel Validation 162
Contact Us 162
Disclaimer 163

List of Tables
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corp, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau SpA, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma Inc, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2017

List of Figures
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Title Date Price
Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report
By QYResearch
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry. The re ...Read More
Apr 2016 $3600.00
China Pharmaceutical Guidebook Series (4) Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medicines
By Access China Management Consulting Ltd
The traditional medicines in Orient, especially, the traditional Chinese medicines are always regarded by occidental as mysterious medicines. Until today not only the chemical composition of tradition ...Read More
May 2015 $750.00
Latest Guide to Chinese Pharmaceutical GMP Regulations
By Access China Management Consulting Ltd
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2012, sales on the Chinese drug market have reached RMB 926.1billion (about US$147 billion) ...Read More
Jul 2015 $750.00
"Acne vulgaris "- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acne vulgaris  - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the disease and ...Read More
Apr 2016 $4950.00
"Acute coronary syndrome(ACS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute coronary syndrome (ACS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of th ...Read More
Apr 2016 $4950.00
"Acute heart failure(AHF)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute heart failure (AHF) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the di ...Read More
Apr 2016 $4950.00
"Acute ischemic stroke (AIS)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the ...Read More
Apr 2016 $4950.00
"Acute lymphoblastic leukemia (ALL)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Acute lymphoblastic leukemia (ALL) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview ...Read More
Apr 2016 $4950.00
"Age-related macular degeneration (AMD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Age-related macular degeneration (AMD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overv ...Read More
Apr 2016 $4950.00
"Alzheimer’s disease (AD)"- Market Insights, Epidemiology and Market Forecast-2020
By Delveinsight
Note*: This report requires 5-10 business days to complete.DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2020” Reports provides an overview of the d ...Read More
Apr 2016 $4950.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

Published By :  Global Markets Direct

For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z